| Diabetes Mellitus, Non-Insulin-Dependent
Brenzavvy vs Soliqua
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Brenzavvy vs Soliqua 100/33 with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSoliqua 100/33 has a higher rate of injection site reactions vs Brenzavvy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Soliqua 100/33 but not Brenzavvy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Brenzavvy
Soliqua 100/33
At A Glance
Oral
Daily
SGLT2 inhibitor
SC injection
Once daily
Basal insulin + GLP-1 receptor agonist
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent 20 mg orally once daily in the morning, with or without food; do not crush or chew the tablet; withhold for at least 3 days prior to major surgery or procedures associated with prolonged fasting.
Diabetes Mellitus, Non-Insulin-Dependent 15 units SC once daily for patients naive to basal insulin or GLP-1 receptor agonist, on a GLP-1 receptor agonist, or on <30 units basal insulin daily; 30 units SC once daily for patients on 30-60 units basal insulin daily; titrate by 2-4 units weekly; max 60 units (60 units insulin glargine/20 mcg lixisenatide) daily; inject within 1 hour prior to first meal of the day.
Contraindications
- Hypersensitivity to bexagliflozin or any excipient in BRENZAVVY
- Hypoglycemia episodes
- Serious hypersensitivity to insulin glargine, lixisenatide, or any excipient in SOLIQUA 100/33
Adverse Reactions
Most common (>=2%) Increased urination, urinary tract infection, female genital mycotic infections, thirst, vaginal pruritus, male genital mycotic infection, hypoglycemia
Serious Diabetic ketoacidosis, lower limb amputation, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum, sepsis, fractures
Most common (>=5%) Nausea, nasopharyngitis, diarrhea, upper respiratory tract infection, headache, hypoglycemia
Serious Anaphylaxis, serious hypersensitivity, acute pancreatitis, hypoglycemia, acute kidney injury due to volume depletion, hypokalemia, acute gallbladder disease, pulmonary aspiration during general anesthesia or deep sedation
Postmarketing Localized cutaneous amyloidosis (insulin glargine); acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation, cholecystitis, cholelithiasis, dysgeusia, dysesthesia, pulmonary aspiration, acute renal failure, alopecia (lixisenatide)
Pharmacology
Bexagliflozin is an SGLT2 inhibitor that blocks renal reabsorption of filtered glucose in the proximal tubule, lowering the renal threshold for glucose and increasing urinary glucose excretion to reduce blood glucose in adults with type 2 diabetes mellitus.
SOLIQUA 100/33 combines insulin glargine, a basal insulin analog that lowers blood glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production, with lixisenatide, a GLP-1 receptor agonist that increases glucose-dependent insulin release, decreases glucagon secretion, and slows gastric emptying.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Brenzavvy
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
Soliqua 100/33
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (7/12) · Qty limit (11/12)
UnitedHealthcare
Brenzavvy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Soliqua 100/33
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Brenzavvy
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Soliqua 100/33
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Brenzavvy.
No savings programs available for Soliqua 100/33.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BrenzavvyView full Brenzavvy profile
Soliqua 100/33View full Soliqua 100/33 profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.